Sign Up to like & get
recommendations!
0
Published in 2020 at "Nature Reviews Rheumatology"
DOI: 10.1038/s41584-019-0367-7
Abstract: Iscalimab, an anti-CD40 monoclonal antibody, showed preliminary efficacy for the treatment of primary Sjögren syndrome (pSS) in a phase II placebo-controlled trial (n = 44). Of the two administration routes tested (intravenous and subcutaneous), only…
read more here.
Keywords:
criteria created;
classification criteria;
disease;
igg4 related ... See more keywords